News | November 23, 2011

University of Alabama at Birmingham to Use "Triggered Imaging" Technology From Varian

November 23, 2011 – The University of Alabama at Birmingham (UAB) Health System became the first medical center in the world last week to utilize intrafraction motion review (IMR), or "triggered imaging," to continually monitor tumor location during radiosurgery for lung cancer.  IMR, which is a unique capability of the TrueBeam linear accelerator from Varian Medical Systems enables visual verification that a tumor is being properly targeted.

"With triggered imaging, clinicians use the imager on the TrueBeam system to observe the targeted tumor repeatedly, at a predetermined portion of the respiratory cycle, in order to check on the tumor's location and trajectory," said Chris Toth, senior director of marketing at Varian.  "If the tumor is not where it is supposed to be, they can halt treatment and intervene to enhance the accuracy of the targeting."

Doctors at UAB used the IMR tool for the first time earlier this month when delivering a Gated RapidArc radiosurgery treatment for inoperable early-stage lung cancer.  RapidArc enables fast, precise image-guided intensity-modulated radiotherapy (IMRT) by delivering dose continuously as the treatment machine rotates around the patient.  Gated RapidArc makes it possible to monitor patient breathing and compensate for tumor motion during a RapidArc treatment. The gating system turns the treatment beam on and off in synchrony with the patient's breathing to increase treatment precision.  With IMR, the gating system also triggers the imager to generate a low-dose X-ray of the targeted tumor at a specific point in the patient's respiratory cycle.

"With IMR, we can now monitor the gating accuracy and ensure that the beam hits the tumor," said Richard Popple, Ph.D., associate professor of medical physics at UAB.  "It will allow us to monitor tumor position in real time and intervene if a change in patient respiratory pattern causes a shift.  The enhanced precision could potentially increase tumor control and decrease the amount of surrounding healthy lung tissues exposed to the beam."

"The IMR tool offers us a way of verifying that our gating strategy remains valid throughout an entire treatment," said Chris Dobelbower, M.D., Ph.D., radiation oncologist at UAB.  "It also gives us the ability to hold the beam should the target wander from isocenter if the patient's breathing pattern were to change due to a cough or a sneeze, or other interference. Those events did not happen with our first patient, so no treatment interruptions were necessary."

To utilize IMR during the treatment for lung cancer, Dobelbower collaborated with thoracic surgeon Douglas J. Minnich, M.D., assistant professor at UAB Healthcare, who placed a set of radio-opaque fiducial markers into the lung tumor using electromagnetic navigational bronchoscopy—an approach that employs three-dimensional computed tomography (CT) imaging to guide the procedure.  These markers made it possible to see the tumor's location within the surrounding healthy tissues using X-ray images generated during treatment.  

"IMR makes it possible to complete lung cancer treatments with a high level of precision and confidence that you're treating the area you want to treat," Minnich said.  "Rather than imaging at the beginning of treatment and then doing your best to account for respiratory motion, IMR allows you to actually watch the tumor and monitor your targeting as the treatment proceeds."

According to Dobelbower, the ability to generate an image with every breath, identify when a targeted tumor has shifted, stop a treatment, and reposition the patient makes a new level of precision feasible.  "This was previously only possible by a time-consuming and cumbersome process of interrupting treatment for additional imaging," he said.  

For more information: www.varianmedicalsystems.com

 

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
Median Technologies Collaborating With Chinese Hospital for Lung Cancer Screening Programs
News | Lung Cancer | December 22, 2017
Median Technologies recently announced a research collaboration agreement with Xingtai People's Hospital, Xingtai City...
Overlay Init